CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).
Rosenberg, JE; Halabi, S; Sanford, BL; Himelstein, AL; Atkins, JN; Hohl, R; Seagren, SL; Bajorin, DF; Small, EJ
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Conference Start Date
Conference End Date